These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38437610)

  • 1. Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20.
    Joyce G; Blaylock B; Chen J; Van Nuys K
    Health Aff (Millwood); 2024 Mar; 43(3):391-397. PubMed ID: 38437610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
    Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of formulary restrictions on medication use and costs.
    Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
    Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
    Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
    Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare coverage of buprenorphine-naloxone film surrounding generic entry.
    Zhang H; Bao Y; Kapadia SN
    Am J Manag Care; 2023 Aug; 29(8):e257-e260. PubMed ID: 37616154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization Management in the Medicare Part D Program and Prescription Drug Utilization.
    Andersen MS
    Forum Health Econ Policy; 2021 Jun; 24(1):1-34. PubMed ID: 36194915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Medicare Part D Prescription Drug Plans and Medication Adherence: A Conceptual Framework and Empirical Analysis.
    Young GJ; Rickles NM; Benzer JK; Dangi A
    Med Care; 2017 Jan; 55(1):37-42. PubMed ID: 27547952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
    Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
    JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries.
    Rao T; Kiptanui Z; Dowell P; Triebwasser C; Alexander GC; Harris I
    JAMA Netw Open; 2020 Mar; 3(3):e200274. PubMed ID: 32119095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare Advantage coverage restrictions for the costliest physician-administered drugs.
    Anderson KE; Alexander GC; Ma C; Dy SM; Sen AP
    Am J Manag Care; 2022 Jul; 28(7):e255-e262. PubMed ID: 35852888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
    DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
    JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
    Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
    Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.